Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 39.59%
As of Monday, July 27, Forte Biosciences, Inc.’s FBRX share price has surged by 39.59%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Commentary & Analysis
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 39.55%
As of Monday, July 27, Forte Biosciences, Inc.’s FBRX share price has surged by 39.55%, which has investors questioning if this is right time to sell.Tudor Pop
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 6.97%
As of Tuesday, July 21, Forte Biosciences, Inc.’s FBRX share price has surged by 6.97%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Down 5.38%
As of Monday, July 13, Forte Biosciences, Inc.’s FBRX share price has dipped by 5.38%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Forte Biosciences, Inc.’s (FBRX) Stock Is Up 7.77%
As of Friday, July 10, Forte Biosciences, Inc.’s FBRX share price has surged by 7.77%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,872.6 | $252.6 | 53% |
|
| Shares Out (Mil) | 17.8 | 52.3 | 29% |
|
| Institutional Ownership | 97.3% | 92.1% | 73% |
|
| Float (Mil) | 18.8 | 40.2 | 28% |
|
| Beta | 2.87 | 0.95 | 97% |
|
| Avg Daily Volume (000s) | 3,392 | 455 | 88% |
|
| Price Change (52-week) |
652.1% | 52.9% | 100% |
|
| Growth | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (8.3%) | (9.9%) | 30% |
|
| EPS (5yr) | 50.5% | 16.0% | 93 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (53.8%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($0.879) | ($3.834) | ($4.038) | |
| Month Ago EPS | ($1.008) | ($4.010) | ($4.142) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($1.050) | ($4.260) | ($4.178) | |
| Year/Year Chg | (29.2%) | (18.7%) | (44.6%) | |
| Financials | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($76) | ($43) | 13% |
|
| EPS (TTM) | ($4.646) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $367 | $180 | 31% |
|
| Valuation | FBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 32.46 | 2.56 | 98% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | FBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (132.3%) | (49.8%) | 4% |
|
| ROE | (188.4%) | (55.5%) | 5% |
|
| Liabilities to Assets | 37.4% | 30.3% | 28% |
|
| F-Score | 1 | 3 | 1% |
|
Forte Biosciences, Inc. did not pass any screens on 7/31/2026.
